Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Muller

Showing results (1171-1180 of 1,237) with videos related to

Pageof 124
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2002
Safe and cost effective use of alteplase for the clearance of occluded central venous access devicesJ P Timoney, M G Malkin, D M Leone, et al.
Frontiers in Neuroscience|September 11, 2023
Machine learning-based classification of chronic traumatic brain injury using hybrid diffusion imagingJennifer J Muller, Ruixuan Wang, Devon Milddleton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2025
Increased ErbB2 signaling is an early adaptation to androgen signaling inhibition and persists in castration resistant prostate cancerJude Owiredu, Betul Ersoy-Fazlioglu, Larysa Poluben, et al.
Cancer Research|March 3, 2016
Rab11-FIP1C Is a Critical Negative Regulator in ErbB2-Mediated Mammary Tumor ProgressionPierre-Luc Boulay, Louise Mitchell, Jason Turpin, et al.
Pediatrics|February 9, 2024
Remdesivir for COVID-19 in Hospitalized Children: A Phase 2/3 StudyAmina Ahmed, Flor M Munoz, William J Muller, et al.
Antimicrobial Agents and Chemotherapy|November 14, 2024
Safety, outcomes, and pharmacokinetics of isavuconazole as a treatment for invasive fungal diseases in pediatric patients: a non-comparative phase 2 trialHeidi Segers, Jaime G Deville, William J Muller, et al.
Infectious Diseases and Therapy|June 17, 2023
Pharmacokinetics, Efficacy, and Safety of a SARS-CoV-2 Antibody Treatment in Pediatric Participants: An Open-Label Addendum of a Placebo-Controlled, Randomized Phase 2/3 TrialHimanshu P Upadhyaya, Jenny Y Chien, Amanda J Long, et al.
Cancer Immunology Research|June 13, 2023
HER2Δ16 Engages ENPP1 to Promote an Immune-Cold Microenvironment in Breast CancerSherif Samer Attalla, Jonathan Boucher, Hailey Proud, et al.
Cancer Research|October 7, 2010
Receptor tyrosine kinase signaling favors a protumorigenic state in breast cancer cells by inhibiting the adaptive immune responseJosie Ursini-Siegel, Sean Cory, Dongmei Zuo, et al.
Cancer Research|November 4, 2005
HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout miceLouise R Howe, Sung-Hee Chang, Kelly C Tolle, et al.
Pageof 124

Showing results (1171-1180 of 1,237) with videos related to

Sort By:
Pageof 124
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2002
Safe and cost effective use of alteplase for the clearance of occluded central venous access devicesJ P Timoney, M G Malkin, D M Leone, et al.
Frontiers in Neuroscience|September 11, 2023
Machine learning-based classification of chronic traumatic brain injury using hybrid diffusion imagingJennifer J Muller, Ruixuan Wang, Devon Milddleton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2025
Increased ErbB2 signaling is an early adaptation to androgen signaling inhibition and persists in castration resistant prostate cancerJude Owiredu, Betul Ersoy-Fazlioglu, Larysa Poluben, et al.
Cancer Research|March 3, 2016
Rab11-FIP1C Is a Critical Negative Regulator in ErbB2-Mediated Mammary Tumor ProgressionPierre-Luc Boulay, Louise Mitchell, Jason Turpin, et al.
Pediatrics|February 9, 2024
Remdesivir for COVID-19 in Hospitalized Children: A Phase 2/3 StudyAmina Ahmed, Flor M Munoz, William J Muller, et al.
Antimicrobial Agents and Chemotherapy|November 14, 2024
Safety, outcomes, and pharmacokinetics of isavuconazole as a treatment for invasive fungal diseases in pediatric patients: a non-comparative phase 2 trialHeidi Segers, Jaime G Deville, William J Muller, et al.
Infectious Diseases and Therapy|June 17, 2023
Pharmacokinetics, Efficacy, and Safety of a SARS-CoV-2 Antibody Treatment in Pediatric Participants: An Open-Label Addendum of a Placebo-Controlled, Randomized Phase 2/3 TrialHimanshu P Upadhyaya, Jenny Y Chien, Amanda J Long, et al.
Cancer Immunology Research|June 13, 2023
HER2Δ16 Engages ENPP1 to Promote an Immune-Cold Microenvironment in Breast CancerSherif Samer Attalla, Jonathan Boucher, Hailey Proud, et al.
Cancer Research|October 7, 2010
Receptor tyrosine kinase signaling favors a protumorigenic state in breast cancer cells by inhibiting the adaptive immune responseJosie Ursini-Siegel, Sean Cory, Dongmei Zuo, et al.
Cancer Research|November 4, 2005
HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout miceLouise R Howe, Sung-Hee Chang, Kelly C Tolle, et al.
Pageof 124